Select Page

The impact of COVID-19 pandemic can be felt across the Healthcare Industry The growing inability in the production and manufacturing processes, in the light of the self-quarantined workforce has caused a major disruption in the supply chain across the sector. Restrictions encouraged by this pandemic are obstructing the production of essentials such as life-saving drugs.

The nature of operation in Pharmaceuticals  plants that cannot be easily stopped and started, makes the operational restrictions in these plants a serious concern for the industry leaders. Restricted and delayed shipments from China have created a price hike in the raw materials, affecting the core of the Healthcare Industry.

The slacking demand from different impacted industries such as automotive is negatively influencing the growth of the Healthcare Industry. In light of the current crisis, the market leaders are focused to become self-reliant which is expected to benefit the economic growth of different economies in the longer term. Companies are triggering events to restructure and recover from the losses incurred during the COVID-19 pandemic.

To remain ‘ahead’ of your competitors, request for a sample here@

Naloxone is an opioid antagonist medicine used in treatment of opioid overdose. Opioids are analgesics which are used for treatment of chronic pain but non-medical use of opioid is rapidly increasing. Opioids produces euphoria along with pain relieving action and hence opioid abuse is increasing worldwide. As per National Institute on Drug Abuse, approximately 130 people die every day as a result of opioid abuse in the United States alone. Naloxone is used for the treatment of opioid overdose. The economic burden of prescription opioid misuse is more than US$ 78.5 billion per year in the United States, which represent significant economic burden and extent of opioid misuse. In 2017, more than 1.7 million people in the United States suffered from substance use disorder related to opioids and currently naloxone is the only effective medicine available for the treatment of the opioid overdose.

Increasing prevalence of opioids overdose expected to fuel the growth of naloxone market. Increasing incidence of opioid drug abuse in the developed as well as developing world expected to drive the growth of naloxone market. The use of opioids for chronic pain management is increasing worldwide and subsequently use of non-medical use of opioids is also increasing which in turn expected to drive the growth of naloxone market.

Increasing awareness about availability of naloxone for the treatment of the opioid overdose further expected to drive the growth of the market. Naloxone when administered shows early onset of the therapeutic action which helps to increase the patient compliance, driving the growth of naloxone market. Easy to administer and measured dose formulations further increases patients as well as healthcare professionals compliance which in turn expected to drive the growth of the naloxone market. Significant amount of the clinical trials undergoing for manufacturing novel dosage form for opioid abuse management expected to drive the growth of the naloxone market. Increasing efforts by healthcare professionals, advocacy groups Non-profit Organizations and government about opioid abuse and availability of the treatment expected to drive the growth of the naloxone market.

To receive extensive list of important regions, ask for TOC here @

The global naloxone market is segmented on the basis of route of administration, distribution channel and region.

By route of administration, market is segmented as:

  • Injectables
    • Intramuscular or Subcutaneous
    • Intravenous
  • Nasal
  • Oral

By distribution channel market is segmented as:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

The global market is expected to experience significant growth over the forecast period due to increasing use of naloxone for the management of opioid overdose. By route of administration, naloxone market is expected to be dominated by injectables due to early onset of action of naloxone. By distribution channel, naloxone market is expected to be dominated by retail pharmacies due to higher patient footfall. The manufacturers in the naloxone market are focusing on getting approval for various dosage forms which in turn expected to enhance the revenue generation in the naloxone market.

The global naloxone market is expected to be dominated by the North America due to higher incidence of opioid overdose in the region. Europe is expected to be second most lucrative naloxone market due to increasing awareness about the treatment for opioid overdose. Latin America expected to experience steady growth in naloxone market owing to gradually increasing use of naloxone for opioid overdose management in the region. Asia-Pacific is emerging market in the global naloxone market due to increasing availability and regional manufacturers in the region. Middle East & Africa is the least lucrative market due to low market penetration of the product in the region. Globally increasing availability of the naloxone and awareness about the opioid overdose expected to be the major drivers in the market.

For in-depth competitive analysis, Check Pre-Book here @

The key market players in the global naloxone market are:

  • ADAPT Pharma, Inc.
  • kaleo, Inc.
  • Amphastar Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Sandoz, SG Pharma Pvt. Ltd.
  • Troikaa Pharmaceu
  • ticals Ltd.
  • Samarth Life Sciences Pvt. Ltd.
  • Somerset Therapeutics LLC

Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape

Throat Lozenges MarketThe growth of the market for throat lozenges will be driven by aging population since elderly people often suffer from throat infection that increase the uptake of throat lozenges. It has been projected by the World Health Organization (WHO) that by 2050 nearly 2 billion populations will belong to geriatric population and it also estimated that global elderly population was 524 million in 2010. For More Information.

Trigeminal Neuralgia Therapeutics MarketGeographically, North America and Europe dominates the global market for trigeminal neuralgia therapeutics due to increased awareness among people about trigeminal neuralgia. However Asia-Pacific accounted as an emerging market in trigeminal neuralgia therapeutics owing to its large number of population. RoW is considered as an untapped market in trigeminal neuralgia therapeutics. For More Information.